MIRVASO (brimonidine tartrate) topical gel 0.33%.
William
W
Abramovits
Ana
A
Prato
Kimberly D
KD
Vincent
Noah
N
Scheinfeld
Aditya K
AK
Gupta
D000279:Administration, Cutaneous; D058647:Adrenergic alpha-2 Receptor Agonists / Q000008:administration & dosage / Q000627:therapeutic use; D000068438:Brimonidine Tartrate; D002986:Clinical Trials as Topic; D003879:Dermatologic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D005782:Gels; D006801:Humans; D011810:Quinoxalines / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D012393:Rosacea / Q000188:drug therapy* / Q000473:pathology
D058647:Adrenergic alpha-2 Receptor Agonists; D003879:Dermatologic Agents; D005782:Gels; D011810:Quinoxalines; D000068438:Brimonidine Tartrate